Plantarfibromatosis: Surgical approach of a giant bilateral case. Plantarfibromatosis or Ledderhose disease is characterized by a benign fibroblastic proliferation of the plantar fascia. It is an illness with unknown etiology and a complex treatment in its most intense manifestation. The authors describe a surgical option for extensive cases where conservative treatments are not successful . Surgical techniques may vary according to the site and extent of the lesions. Surgical treatment with wide resection of the lesion and second intention healing using a hydrocolloid dressing. After a 3-year follow-up with no recurrence, the authors demonstrated an excellent result, which led to an important improvement in the patient's quality of life. Surgical treatment can be a good option for plantar
Study to Assess EN3835 in the Treatment of PlantarFibromatosis (Also Known as Ledderhose Disease) This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease). undefined
Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of PlantarFibromatosis This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of up to 2 treatments of EN3835 vs placebo in participants with plantarfibromatosis. undefined
Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of PlantarFibromatosis Assess the long-term safety and efficacy of EN3835 in participants who have participated in a parent placebo-controlled study of EN3835 and assess the efficacy and safety of EN3835 in the treatment and retreatment of PlantarFibromatosis. undefined
in or subscribe to access all of BMJ Best PracticeTreatment algorithmONGOINGall patientsLog in or subscribe to access all of BMJ Best PracticeContributorsVIEW ALLAUTHORSMartha Anderson, DPM, FACFASAcknowledgementsVIEW ALLPEER REVIEWERSMark A. Hardy, DPM, FACFASMolly Judge, DPM, FACFASPatrick J. McKee, DPMDifferentialsPlantar fascia ruptureHeel fat pad syndrome (fat pad atrophy)Proximal plantarfibromatosis
/musculoskeletal 111.1 Dupuytren’s disease of the hand 111.2 Plantarfibromatosis (Ledderhose disease) 161.3 Plantar fasciitis 181.4 Heterotopic ossification of the hip 201.5 Pigmented villonodular synovitis (PVNS) / tenosynovial giant cell tumour (TSGCT) 242 Skin/soft tissues 262.1 Keloid scarring 262.2 Actinic keratosis (AK) and cutaneous Bowen’s disease (SCC in situ fibromatosis (Ledderhose disease)1.2.1 RT seems to be an effective modality of treatment for plantarfibromatosis, with good local control and symptomatic benefit (Grade B).1.2.2 The recommended total dose would be 30 Gy in ten fractions, given in two separate phases of 15 Gy in five daily fractions, with 12 weeks between the two phases (Grade B). The RT can be delivered using orthovoltage photons
). Plantar fasciitis and fibromatosis Advanced imaging is considered medically necessary in EITHER of the following scenarios: * Evaluation for plantar fasciitis following a failure of at least 6 months of treatment, including at least two of the following: mechanical de-weighting, foot orthosis, night splints, taping, or manual therapy * Diagnosis and management of plantarfibromatosis when ultrasound
fasciitis following a failure of at least 6 months of treatment, including at least two of the f ollowing: mechanical de-weighting, foot orthosis, night splints, taping, or manual therapy • Diagnosis and management of plantarfibromatosis when ultrasound cannot be performed or is nondiagnostic and following a failure of at least 3 months of conservative management including corticosteroid injections
, foot orthosis, night splints, taping, or manual therapyDiagnosis and management of plantarfibromatosis when ultrasound cannot be performed or is nondiagnostic and following a failure of at least 3 months of conservative management including corticosteroid injectionsIMAGING STUDYMRI lower extremityCT lower extremity when MRI cannot be performedTraumaAcute traumatic injuries –not otherwise
(not localized to one site).Plantar fasciitis and fibromatosisAdvanced imaging is considered medically necessary in EITHER of the following scenarios:Evaluation for plantar fasciitis following a failure of at least 6 months of treatment, including at least two of the following: mechanical de-weighting, foot orthosis, night splints, taping, or manual therapyDiagnosis and management of plantarfibromatosis when
fasciitis and fibromatosisAdvanced imaging is considered medically necessary in EITHER of the following scenarios:Preoperative evaluation for plantar fasciitis following a failure of at least 6 months of conservative management, including at least two of the following: mechanical de-weighting, foot orthosis, night splints, taping, or manual therapyDiagnosis and management of plantarfibromatosis when
Sorafenib in Dupuytren and Ledderhose Disease. Palmar and plantarfibromatosis are benign proliferative processes which present as a diffuse thickening or nodules of the hands and/or feet and may lead to flexion contractures, pain, and functional impairment known as Dupuytren and Ledderhose diseases, respectively. Current treatments are noncurative and associated with significant morbidity. Here
to evaluate a focal abnormality such as plantar fasciitis, plantarfibromatosis, Morton neuroma, a ganglion cyst, or a tenosynovial giant cell tumor of the tendon sheath but may also be used to evaluate for a muscle, tendon, or ligament tear/rupture, tendinosis, tenosynovitis, joint effusion, and nerve pathology. An ultrasound examination of the ankle is divided into 4 regions (anterior, medial, lateral